. These transplantation studies suggest the presence of stem cells throughout the mammary gland during the life of an animal.
A relationship between the presence of stem cells and the predisposition to carcinogenesis exists in the mammary gland. The greatest concentration of stem cells are found in end-buds and terminal ducts and it is these ductal structures within the pubertal mammary gland which are more susceptible to tumorigenesis. This association can be demonstrated in rodents with chemicals such as 7, 12-dimethylbenz [a] anthracene and N-nitrosomethylurea (NMU) whose carcinogenic effectiveness decreases after 50 days (puberty), which correlates with the presence of terminal end-buds (TEBs) and terminal ducts (Huggins et al. 1961; Dao 1969; Gullino et al. 1975; Russo et al. 1977) . These ductal structures are present in greater numbers in prepubertal and adolescent women (Dawson 1934) and it is this age-group of Japanese victims of the Hiroshima and Nagasaki atomic detonations that were most susceptible to carcinogenesis induced by resulting irradiation (McGregor et al. 1977) .
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᭧ 1998 Blackwell Science Ltd, International Journal of Experimental Pathology, 79, [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] Figure 1. Schematic diagram of the ductular structures in the developing mammary gland. TEB, terminal end-bud; TEB clefted, terminal end bud partially divided by a cleavage furrow at its apex, further cleavage results in alveolar buds; LBs, lateral buds; ABs, alveolar bud; AL, alveolar lobule. Classification of lobules: type 1 (lob 1), synonymous with lobule of ABs; type 2 correspond to ALs containing smaller numbers of larger ductules (lob 2); type 3 are ALs containing larger numbers of smaller ductules (lob 3). Modified from Russo & Russo (1987) and Rudland (1993) . (cc) and is absent in the luminal epithelial cells (lec) (outlined arrows) which line the lumen (lum). Magnification × 720. Bar ¼ 20 mm. B. Schematic representation of staining patterns. Actin/myosin antisera moderately stain peripheral cap cells (dotted circles) and this staining increases in peripheral cells (p) which are closer to the subtending duct until they merge with myoepithelial cells (m) of the duct (black ovoids). Central cells are only weakly stained by antisera to actin/myosin (dotted squares). Differential staining for the basement membrane proteins, laminin and Type IV collagen, occurs in the TEB. A thin band of staining is present at the apical tip and becomes thicker around the TEB and the subtending duct. Modified from Rudland (1993) .
Thus stem cells provide a population of cells in the breast with the ability to create a secretory parenchyma during normal mammary development. In addition, neoplastic development of the mammary gland appears to be associated with the greater susceptibility of stem cells to carcinogenesis. This review focuses on the work performed in our laboratories on the biology of stem cells and how control of their growth is linked to the normal and neoplastic development of the mammary gland.
Cellular composition of normal and neoplastic mammary glands
The normal mammary gland is composed of two compartments separated by a basement membrane (Rudland 1993) . The branching system of ducts constitutes the mammary parenchyma which is embedded within a mesenchyme containing clusters of adipocytes, permeated by fibroblasts, nerves and blood vessels. During the development of malignant tumours, the density of the blood vessels increases and the basement membrane and the fatty environment are reduced or lost completely (Folkman et al. 1989; Aung et al. 1993) .
The normal mammary parenchyma consists of three main cell types. Epithelial cells form the lining of ducts, and alveoli are lined by the alveolar cells which are responsible for the secretion of milk products, including casein, during lactation. Both cell types are surrounded by a sometimes discontinuous layer of myoepithelial cells situated adjacent to the basement membrane (Ozzello 1971) . Epithelial, myoepithelial and, if the animal or patient is pregnant, alveolar cells are present in benign hyperplastic and neoplastic lesions in the mammary gland. However, only epithelial cells are present in malignant carcinomas of rodents and humans; no myoepithelial or secretory alveolar cells are present even if the subject is pregnant (Rudland 1987 (Rudland , 1993 .
Histochemical and immunocytochemical reagents can identify the main cell types in normal and neoplastic mammary tissue (Rudland 1993) . Furthermore, these reagents have immunolocalized subsets of epithelial and myoepithelial cells, and cells intermediate between these cell types which occur particularly in growing endbud structures (Figure 2) (Rudland 1991) . Cap cells line the apex of the end-bud and are stained by both epithelial-and myoepithelial-specific markers. Cytochemical staining with these markers diverge from cap cells towards cortical cells for epithelial-specific markers and towards peripheral cells for myoepithelial-specific markers. This staining pattern suggests that cap cells in the end-bud contains stem cells which can differentiate into epithelial or myoepithelial cells. Similar properties are found in single-cell-cloned epithelial cell lines, such as Rama 25, 37 and 704, derived from normal and benign lesions of rat and human glands which differentiate, in a stepwise manner, to myoepithelial-like and secretory alveolar-like cells in culture. Cell lines of the intermediate cells along the myoepithelial pathway have also been isolated (Rudland 1987 (Rudland , 1993 Reviewed in detail previously (Rudland 1987 (Rudland , 1993 .
human breast carcinomas fail to produce single-cellcloned epithelial cell lines that differentiate to a myoepithelial or alveolar cell phenotype in culture (Figure 3 ), and this result correlates with the disappearance of the myoepithelium and the inability to give rise to alveolar cells in breast carcinomas. The absence of the myoepithelial cell layer represents the loss of the growthstimulatory environment produced by these cells which is normally additional to that provided by the basement membrane and fatty stroma. The intercellular signals regulating growth of the three main parenchymal types are now considered using the cell lines shown in Table 1 .
Hormonal agents and micronutrients
The growth of the mammary gland is regulated by the systemic levels of mammatrophic hormones. Estrogen promotes growth of ducts whereas progesterone stimulates lobuloalveolar development, and prolactin induces the differentiation of alveoli (Lyons 1958; Nandi 1958) . Mammary development in vivo also requires hydrocortisone and insulin which are thought to synergise with the three primary mammatrophic hormones (Figure 4 ) (Topper & Freeman 1980) . In addition, the stromal compartment of the mammary gland produces local trophic factors which are involved in the regulation of mammary development, since rodent parenchymal tissues and cells will grow when transplanted into the mammary fat pad, but not when transplanted subcutaneously (DeOme et al. 1959 ).
The malignancy of tumours in the mammary gland is inversely related to their requirement of systemic hormones for growth. Benign tumours, e.g. the carcinogeninduced tumours of rats (Huggins et al. 1961 ) and the spontaneously arising benign tumours of humans (Hinton et al. 1986) , are structurally similar to the normal mammary gland and require mammatrophic hormones to grow, as do some (low-grade) malignant tumours of rats (Williams et al. 1985) and humans. These mammary cancers are classified as hormonedependent tumours and comprise 25-30% of all human carcinomas (Vorherr 1980) . The remaining 70-75% of human malignant tumours no longer require mammatrophic hormones for growth and are therefore known as hormone-independent. Furthermore, the fat pad is required for growth of hyperplastic rodent lesions but not for neoplastic growth of lesions (DeOme et al. 1959) , which suggests that changes in both local and systemic growth control occur in the development of breast carcinoma.
The general lack of growth-stimulatory effects by mammatrophic hormones in vitro led to the identification of agents which stimulate DNA synthesis and division directly in mammary cells (Sirbasku 1978) . A number of growth-promoting agents have been discovered in culture studies with defined media which may be classified as essential nutrients. One of the most important cellular micronutrients is iron and the iron-binding protein, transferrin, is essential for the growth of many cells in defined culture medium including our mammary cell lines (Rudland et al. 1977) . In addition to transferrin, haemoglobin and ferritin promote growth of the Rama 37 mammary epithelial cell line (Wilkinson et al. 1998 ) which suggests that the requirement of iron may be an artefact of the culture system. However, transferrin constitutes 2% of the total cytosolic protein in pregnant and lactating mammary tissue (Keon & Keenan 1993) which also contains proliferating cells that possess a high number of transferrin receptors (Walker & Day 1986 ). Transferrin and its mRNA are also present within the developing rat mammary gland. These reports suggest that transferrin can act like a growth factor, either in an autocrine or paracrine manner if the protein is produced locally, and/ or in an endocrine manner if levels within the circulation vary considerably.
MCF-7 breast carcinoma cells secrete transferrin in culture and its secretion is stimulated by oestrogen and reduced by tamoxifen (Vandewalle et al. 1989) . Cell lines from malignant breast tumours contain a higher number of transferrin-receptors per cell compared to those which are derived from nonmalignant sources ( Table 2) . Medium containing oestrogen results in higher numbers 196 P. Li et al. (Rudland 1987 (Rudland 1993 ).
of transferrin-receptors for the MCF-7 breast cancer cell line, but not when they are cultured in medium antagonistic to oestrogen action. Furthermore, 71% of invasive breast carcinomas contain cells which overexpress transferrin-receptors. Thus, the growth of breast carcinomas may, at least in part, be enhanced by a hormonally controlled autocrine loop involving the overexpression of transferrin and its receptor.
Mammary growth-stimulating activity in pituitary glands
Prolactin, like oestrogen and progesterone, has little effect on the growth of cultured mammary cells. However, pituitary extracts are mitogenic for many cells (Sirbasku et al. 1982 ) including the Rama cell lines. Pituitary-derived mammary growth factor (PMGF) stimulates growth of Rama 25 epithelial but not the Rama 29 myoepithelial-like cells. Although it has only been partially purified, PMGF is distinguishable from bovine prolactin, growth hormone and other known growth factors which occur in the pituitary gland Wilkinson et al. 1998) . The activity of PMGF is higher from the pituitary glands of lactating or perphenazinetreated rats than in untreated virgin females which suggests that the growth factor has a role to play in mammary development in vivo . Despite both originating from the pituitary gland and probably under similar hypothalamic control, prolactin stimulates the production of casein in alveolar-like cells as observed in confluent epithelial cultures (Warburton et al. The Kd and number of receptors were calculated from the data pooled from at least two independent binding experiments and presented as the meanϮstandard error. The binding of [ 125 I] diferric transferrin was performed and analysed as described previously (Fernig et al. , 1992 . differentiation of epithelial cells rather than proliferation which is stimulated by PMGF.
A growth response to PMGF is stimulated in epithelial cells in culture derived from benign tumours which regress in vivo after administration of antipituitary agents (Segaloff 1978; Hinton et al. 1986 ). However, hypophysectomy of rats or humans does not cause the regression of advanced tumours (Kim 1979; Vorherr 1980) nor does PMGF promote growth of rat (Rama 800, Rama 900) or human (Ca2-83) breast carcinoma cell lines which are highly malignant in nature. PMGF can still stimulate weakly metastasizing rat cell lines (Rama 600) and hormone (including pituitaryablative) therapy can aid about a quarter of all human breast cancers. The loss of differentiative ability and failure to respond to pituitary-derived growth factors are steps in the progression of the normal cell towards malignancy.
Growth factors of the epidermal growth factor family and their receptors
Transforming Growth Factor-a (TGFa) is the most abundant growth factor of the epidermal growth factor (EGF) family in the mammary gland. Myoepithelial-like (Rama 29) and, to a lesser extent, epithelial (Rama 25) cells in culture secrete mature, bioactive TGFa which has a molecular weight of 5616 D and is also found in the rat mammary gland in vivo ( Figure 5A ,B) (Smith et al. 1989) . This is in agreement with immunofluorescent studies using antisera raised to TGFa which stained Rama 29 myoepithelial-like cells more intensely than Rama 25 epithelial cells. Cytochemical staining of immunoreactive (ir)-TGFa was also strongly associated with the myoepithelium but only weakly in the epithelial cells in the developing rat mammary gland. The intermediate cells within growing end-buds are stained at an intermediate level ( Figure 5A,B) . Alveolar secretions are also stained strongly for TGFa in lactating glands. However, the effects of TGFa (Smith et al. 1989) , like those of EGF are not restricted to a specific mammary cell type since TGFa stimulates the growth of fibroblastic, myoepithelial-like and epithelial cell lines from normal rat mammary glands and benign tumours. A paracrine or an autocrine role for TGFa in the mammary gland is suggested by the observation that the levels of the growth factor secreted by Rama 29 myoepithelial-like cells are sufficient to stimulate growth of the myoepithelial-like cells themselves, or of epithelial or stromal cell lines (McAndrew et al. 1994a) .
Western blotting of ir-TGFa in extracts of rat mammary tissue and cell lines reveals that it is a protein with a molecular weight of 50 kD whose levels are higher than would be expected from the amount of bioactive TGFa detected in the same extracts. TGFa mRNA is found in the Rama 27 mammary fibroblast cells which are also stained by TGFa antiserum as are rat mammary fibroblasts in vivo (McAndrew et al. 1994b ). However, bioactive TGFa is not secreted by Rama 27 cells. These results indicate that growth control of the mammary gland by TGFa is complex in nature.
TGFa binds to the same receptor as EGF. Our rat mammary epithelial, myoepithelial-like and fibroblastic cell lines possess high-affinity EGF receptors (EGFR) with dissociation constants ranging from 0.4 nM to 1.3 mM for TGFa (Smith et al. 1989; Fernig et al. 1990) . No alteration in EGFR numbers occurs when epithelial cells differentiate along the myoepithelial-like pathway in vitro ). This concurs with the view that locally produced TGFa may promote the proliferation of epithelial, intermediate and myoepithelial cell types in vivo.
Overexpression of TGFa and its receptor, EGFR, may be involved in the abnormal growth of malignant breast cells. This notion is supported by the detection of ir-TGFa in 30-70% of human breast carcinomas ( Figure 5C ) (Lundy et al. 1991; Umekita et al. 1992; McAndrew et al. 1994a ) and that transgenic mice overexpressing TGFa are more prone to mammary cancers (Sandren et al. 1995) . In a similar fashion to its counterpart in normal mammary cells, ir-TGFa in breast carcinomas appears as a 50 kD protein and its relationship to the mature, bioactive TGFa is unknown (McAndrew et al. 1994a ). However, a rapidly growing tumour, due to an uncontrolled TGFa/EGFR autocrine loop, such as that found in squamous carcinomas of the head and neck (Cowley et al. 1984) , is not found in breast carcinomas. These breast tumours are relatively slow growing and still under a degree of hormonal control during the early stages of malignancy. These observations suggest that the progression to an oestrogen-refractory state is more gradual in the development of a breast carcinoma in which changes in the TGFa/EGFR axis may play a vital contribution. The c-erbB-2 protooncogene encodes a 185 kD tyrosine kinase which is structurally related to the EGFR. The c-erbB-2 receptor is expressed in 20-30% of invasive breast carcinomas (Slamon et al. 1987; McCann et al. 1989; Winstanley et al. 1991 ) of which there is an inverse correlation between patient survival and c-erbB-2 expression, particularly in patients with no involved lymph nodes (Slamon et al. 1987; Winstanley et al. 1991) . However, c-erbB-2 receptors have been immunolocalized on epithelial and alveolar cells during caprine mammary development and these have been suggested to be a potential population of stem cells (Li et al. 1998) , whilst transfection of the rat equivalent of the c-erbB-2 gene, neu, enabled normal rodent mammary epithelial cells to secrete casein the presence of prolactin (Marte et al. 1995) . Such reports suggest that c-erbB-2 receptor may play a role in the development and differentiation of the mammary gland as well as in breast neoplasia.
Fibroblast growth factors in normal mammary development
The Fibroblast Growth Factors (FGFs) form a family of growth factors whose effects are mediated by two types of receptors on mammary cells. High-affinity tyrosine kinases are ultimately responsible for generating the primary intracellular signals, whilst low-affinity heparan sulphate proteoglycans (HSPGs) are a type of glycosaminoglycan which can store and activate FGFs to enable binding to the high-affinity receptor (Fernig & Gallagher 1994 ). In our cell lines, bFGF and the high-(Kd 30-280 pM; approximately 2 × 10 4 per cell) and low-affinity (Kd 1-20 nM; approximately 3 × 10 6 per cell) receptors for the growth factor are produced by the myoepitheliallike cells and, to a lesser extent, the intermediate cells.
Epithelial cells do not synthesize either type of receptor nor the growth factor itself Barraclough et al. 1990; Ke et al. 1993) . Both cell lines produce amounts of bFGF (6-7 ng/10 6 cells) which are sufficient to stimulate the growth of myoepithelial-like and intermediate cell lines and this result suggests the possibility of autocrine/paracrine control of mammary cell growth in vivo. It should be noted that between one-half and two-thirds of the HSPG low-affinity receptors for bFGF are associated with the basement membrane/extracellular matrix in vitro (Fernig et al. 1992) (Figure 6 ) and this has been confirmed by immunocytochemistry . In resting mammary glands, bFGF is associated with the myoepithelial cells and the basement membrane, whereas in growing glands, bFGF is localized to individual cells, in particular, the intermediate stem cells of the end-bud ( Figure 6 ). However, the presence of the bFGF HSPG receptors enhances the staining of the basement membrane/ myoepithelial cell when bFGF antisera is preincubated with native bFGF, and then used for immunocytochemical staining of mammary tissue .
Ectopic expression of FGFs in malignant tumours
Rodent and human mammary epithelial cell lines derived from malignant tumours possess receptors for bFGF. These are high-affinity, cell surface receptors which have a Kd in the range of those found on normal myoepitheliallike cells (Fernig et al. , 1992 Ke et al. 1993) . Neither rat nor human mammary epithelial cells derived from the normal mammary gland or benign tumours produce detectable levels of FGF receptors. Therefore the expression of high-affinity receptors by malignant mammary epithelial cells in vivo is ectopic. bFGF is a potent stimulator of malignant mammary epithelial cell proliferation (Peyrat et al. 1992; Karey & Sirbasku 1988; Stewart et al. 1990) , despite the fact that only low levels of low-affinity HSPGs for bFGF are found on these cells. These results suggest that the low levels of HSPGs produced by the malignant cells, at least in the rodent, can activate bFGF (Chen et al. 1995) . This would indicate that the dual receptor system for FGFs (Fernig & Gallagher 1994 ) is fully functional in malignant cells despite the apparent loss of most of the HSPG lowaffinity receptors (Figure 6 ). These results have been confirmed on pilot studies of human breast specimens (Takahashi et al. 1989; Peyrat et al. 1992) .
A bFGF growth-stimulatory activity is found in one in four human mammary carcinoma cell lines as well as in extracts of rat mammary carcinoma (Luqmani et al. 1992; Fernig et al. 1993; Anandappa et al. 1993) . Expression of bFGF mRNA has also been detected in human breast carcinomas but the levels are lower compared to those found in normal and benign mammary tissues (Luqmani et al. 1992; Anandappa et al. 1993) . These results correlate with the loss of myoepithelial cells in invasive carcinomas (Rudland 1993) , since it is these cells which produce bFGF in cell lines derived from normal and benign mammary tissues. However, 25% of malignant tumours express bFGF mRNA at levels which are equivalent or higher than those in benign tissues (Anandappa et al. 1993) . Isolation of bFGF from malignant breast tumours (Rowe et al. 1986 ) suggests that expression of bFGF mRNA by human carcinomas results in the synthesis of active bFGF polypeptides (Figure 6 ).
Protein markers of differentiation to myoepithelial cells
Changes in the expression of proteins mark discrete cellular stages of the differentiation pathway of our rat mammary epithelial stem cell lines to myoepithelial-like cells in culture (Paterson & Rudland 1985) . A calciumbinding regulatory protein, p9Ka (Barraclough et al. 1987) , also known as S100 A4 (Schafer et al. 1995) increases relatively early, keratin 14 increases in the middle stages and Thy-1 increases later on (Paterson & Rudland 1985) . In contrast, the basement membrane proteins, laminin and Type IV collagen, increase relatively evenly throughout the differentiative pathway from an epithelial to a myoepithelial-like cell ). The stages of synthesis at which the production of the proteins are controlled varies with each protein. p9Ka and Thy-1 appears to be regulated at the mRNA level (Barraclough et al. 1984 (Barraclough et al. , 1987 , whilst both laminin and Type IV collagen are regulated post-transcriptionally ). These changes in protein expression correlate with the levels of the marker proteins observed by immunocytochemistry in the end-buds of growing rats (Rudland 1987) and in human intermediate cell types in vitro and in vivo (Aung et al. 1993; Rudland et al. 1998) . The protease, Cathepsin D, and the extracellular protein, hyaluronectin (HN), are also early marker proteins of myoepithelial cells which can be observed at lower levels in intermediate cells in endbuds but not in epithelial cells in vivo (Table 3) .
The role of p9Ka has been investigated further since it was one of the first proteins detected during the differentiation of an epithelial to a myoepithelial cell (Paterson & Rudland 1985) . When p9Ka genomic DNA was 200 P. Li et al. transfected into rat mammary epithelial cells, intermediate/myoepithelial cell colonies were produced at a higher frequency than in controls (Table 4) . Antisera raised against rat p9Ka immunolocalized to the cellular cytoskeleton of cultured rat myoepithelial cells ( Figure 7A ,B) (Davies et al. 1993 ) and scrape-loading of recombinant p9Ka into epithelial cells caused similar changes in the cytoskeleton within 48 h ( Figure 7C ). These results suggest that p9Ka may play a role in the initiation of differentiation to a myoepithelial cell phenotype by binding to the cellular cytoskeleton. This proposed function correlates with the site of action on the cytoskeleton, however, the precise binding target of p9Ka has been controversial with reports suggesting binding of p9Ka to actin (Watanabe et al. 1993 ), tropomyosin (Takenaga et al. 1994 ) and nonmuscle myosin (Kriajeska et al. 1994; Ford & Zain 1995) . Although p9Ka occurs cytoplasmically in intermediate cells within end-buds in growing glands ( Figure 7D ), the protein has been associated with filamentous material adjacent to the myoepithelial cells ( Figure 7E ). How the intracellular and extracellular forms of p9Ka are related is not known but variant forms of the protein detected in different subcellular fractions (Barraclough & Rudland 1994 ) may explain its unusual topographical distribution in mammary cells.
Appearance of intermediate markers of the myoepithelial pathway in carcinomas
The loss of the myoepithelial cell in advanced malignant carcinomas of rats and human should preclude the expression of protein markers of the myoepithelial pathway as has been observed for smooth-muscle actin and myosin (Gusterson et al. 1982; Dunnington et al. 1984) . However, other myoepithelial markers are still present in tumours which may represent a limited ability of the carcinoma cells to differentiate along this pathway, such that 39/42% of breast carcinomas express laminin/Type IV collagen, 14% express keratin 14 and 60% of breast carcinomas express p9Ka ( Figure 7F ) . Cathepsin D and hyaluronectin, which occur early in the differentiation of the myoepithelial cell, are observed in 50-60% of breast carcinomas (Table 3) . Benign breast disease and benign tumours possess all marker proteins characteristic of the myoepithelial cell (Table 3) Aung et al. 1993; Winstanley et al. 1993) . These markers can also be detected in some human breast carcinoma cell lines (unpublished results) which suggests that malignant carcinoma cells retain some characteristics of myoepithelial cells.
Conclusion
The normal mammary gland consists of three parenchymal cell types which arise from a population of epithelial stem cells in end-buds of growing glands. These cells are intermediate in morphology and cytochemical staining between epithelial and myoepithelial cells, and correspond to the intermediate epithelial stem cell lines in culture (Rudland 1993 
The presence of myoepithelial-related proteins in other mammary cell types in vivo in either the cytoplasm (c) or in filaments (f) using immunocytochemical detection methods is shown. Key: þ þ , þ , Ϯ and -; present in 75-100%, 25-75%; 5-25% and < 5% of cells or carcinomas, respectively (Aung et al. 1993; Barraclough et al. 1998; Winstanley et al. 1993) . Immunocytochemical data for hyaluronectin (HN) from P. S. Rudland and D. West (unpublished) . (Paterson & Rudland 1985) after DNA transfection with Ha-ras-1 cDNA or rat p9Ka cDNA coupled to the selectable vector pSV2neo, as described previously (Davies et al. 1993 ). be caused by partial differentiation of the malignant cell along the myoepithelial pathway, at least for the TGFa/ EGFR autocrine loop. Autonomous growth and hormonal independence can also be imparted by the overexpression of the EGFR-related c-erbB-2 which is true of 20% of breast carcinomas expressing this receptor . Differentiation of epithelial cells along the myoepithelial pathway may also lead to a decline in the responsiveness to the growth stimulatory ability of PMGF and lead to pituitary-independent growth. Malignant cells which retain certain characteristics of this pathway may account for the inability of carcinoma cells to respond to hormonal growth stimuli (Figure 8) . Autocrine and paracrine loops involving growth factors and their receptors can stimulate cell growth in the mammary gland. Downregulation of growth factormediated cell growth may be caused by the differentiation of the epithelial/stem cell to a secretory alveolar or myoepithelial cell both of which are nonproliferating in phenotype (Joshi et al. 1986 ), as well as by sequestration of certain growth factors through HSPGs (Fernig & Gallagher 1994) . The inability of the malignant cell to produce a terminally differentiated secretory cell or myoepithelial cell may contribute to its tendency towards uncontrolled cell growth in vivo (Figure 8) . Figure 8 . A potential molecular model for mammary development. Stem cells in the normal mammary gland and in benign lesions can differentiate to ductal epithelial and then to alveolar-like cells or to myoepithelial-like cells. Fully differentiated secretory alveolar and myoepithelial cells are terminally differentiated (term) being unable to proliferate. The differentiative capacity of the stem cells is largely lost in the malignant state, especially during the terminal phases. The absences of products of myoepithelial cells in malignant tumours is compensated for by their ectopic production and/or production of related molecules in some rat and human mammary carcinomas.
